Newco Akribion Therapeutics GmbH has raised €8 million (US$8.3 million) in a seed round to develop a new and potent class of RNA-targeted CRISPR nucleases, which, rather than cleaving specific nucleic ...
Curently the only available blood test to tell which women are at risk of postpartum depression (PPD) is the one that ...
Aussie radiopharma company Advancell Co. Ltd. closed an oversubscribed $112 million series C round that will accelerate clinical development of its pipeline of radionuclide therapies and allow it to ...
Researchers at the University of California at San Francisco have identified an RNA-binding protein that increased the translation of Myc mRNA. The authors wrote that their work, which was published ...
New hires and promotions in the biopharma industry, including: Allogene, Alumis, Beximco, Clarametyx, Commit, Concerto, OS Therapies, Precision, Roche, Scholar Rock. Copyright ©2025. All Rights ...
Japan’s drug pricing scheme has gotten more complicated, and pharma companies should brace themselves for annual price cuts.
New hires and promotions in the biopharma industry, including: Allogene, Alumis, Beximco, Clarametyx, Commit, Concerto, OS Therapies, Precision, Roche, Scholar Rock. Copyright ©2025. All Rights ...
HCW Biologics Inc. has received clearance of its IND application from the FDA to initiate a first-in-human phase I trial to ...
The U.K. Medicines and Health Care Products Regulatory Agency has provided guidance on what does and does not constitute a regulated digital mental health technology, but developers should be aware ...
As the number of mega-mergers have increased in recent years, and the purchase price of innovative companies rises, it is apparent that many lucrative buyouts fail to meet expectations, although a few ...
The first successful phase II trial in Duchenne muscular dystrophy (DMD) heart disease rolled out from Cumberland Pharmaceuticals Inc., which said top-line findings from the experiment called Fight ...
New and positive data for Maia Biotechnology Inc.’s lead candidate for a particularly deadly and advanced lung cancer propelled the stock modestly higher on Feb. 4. The pivotal phase II THIO-101 study ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback